Navigation Links
AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols Suppress MMP1 and Stimulate Collagen Through TNF-a Signaling
Date:2/11/2008

Clinical Data Presented at the 66th Annual Meeting of the American Academy

of Dermatology

FREEPORT, N.Y., Feb. 11 /PRNewswire/ -- AGI Dermatics clinical research indicates that the ability of bicyclic monoterpene diols (BMTds) to reduce collagenese MMP-1 secretion and increase collagen production is dependent on the TNF-a signaling in the fibroblasts. The data was presented at the Poster Session at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio.

"Our prior research showed that BMTds increase collagen gene expression and protein production while decreasing MMP-1 secretion," said Daniel Yarosh, PhD, President, AGI Dermatics. "This study gives us insight into the cellular communication that allows BMTds to work so effectively and efficiently in treating photodamaged skin."

BMTds, a class of compounds known to increase nitric oxide levels, were recently reported to play a major role in collagen synthesis. AGI scientists questioned whether the transmission of BMTd factors were influenced by the role of Interleukin-6 (IL-6) and TNF-A in regulating collagen 1 and MMP-1 secretions.

In earlier studies of BMTds, AGI scientists observed a linear increase in BMTd concentrations and secretion of interleukin-6 (IL-6), a multi-functional cytokine that mediates a wide variety of functions in cells, promotes cell proliferation and regulates gene expression. By blocking the IL-6 signaling with a neutralizing IL-6 antibody, studies showed a concomitant increase in MMP-1 and a reduction in collagen 1. The effect of the neutralizing antibody, however, was gradually overcome by increasing BMTd concentrations, indicating that IL-6 is not involved in the transmission of the BMTd effect. Results indicated a linear decrease in MMP-1 secretion and an increase in collagen production, two key components in treatment of photoaged skin.

Similarly, blocking TNF-a signaling in the fibroblasts with a TNF-a neutralizing antibody also increases MMP-1 and decreases collagen secretion. However, blocking TNF-a signaling also blocks the BMTd effect.

AGI Dermatics is the developer of Remergent, a doctor-dispensed skincare line based on the science of DNA repair. Pinoxide, an exclusive and patented blend of bicyclic monoterpene diols, is formulated in Remergent Microcirculation Therapy.

About AGI Dermatics

AGI Dermatics is the bio-pharmaceutical laboratory that has led research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell- signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. http://www.agiderm.com


'/>"/>
SOURCE AGI Dermatics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology:
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
Breaking Medicine News(10 mins):